A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL)

Trial Profile

A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Everolimus (Primary) ; Dexrazoxane; Doxorubicin; Pegaspargase; Prednisone; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 04 Aug 2016 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top